In vitro antimicrobial susceptibility of Helicobacter pylori strains isolated in Chile;Susceptibilidad in vitro de cepas de Helicobacter pylori: Aislamiento de cepas resistentes a claritromicina

Revista Medica de Chile

Volumn 129, Issue 6, 2001, Pages 643-646

  González C , Carlos ^a   García C , Apolinaria ^b   Daroch M , Fabiola ^b   Kawaguchi P , Fernando ^b   Solar R , Henry ^b   Rivera F , Nancy ^b   Vega C , Edith ^b  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

^b NONE

Author keywords

Amoxicillin; Antibiotics; Bismuth; Helicobacter pylori; Metronidazole

Indexed keywords

AMOXICILLIN; ANTACID AGENT; ANTIINFECTIVE AGENT; BISMUTH; CLARITHROMYCIN; METRONIDAZOLE; PENICILLIN DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; HELICOBACTER PYLORI; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION;

AMOXICILLIN; ANTACIDS; ANTI-BACTERIAL AGENTS; BISMUTH; CLARITHROMYCIN; DRUG RESISTANCE, MICROBIAL; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; PENICILLINS;

EID: 0035376089     PISSN: 00349887     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. BLASER MJ. Hypothesis for the pathogenesis and natural history of Helicobacter pylori-induced inflammation. Gastroenterology 1992; 102: 720-7.
2. DE FIGUEIREDO T, DE MAGALHAES DM, NOGUEIRA A, AGUIAR G, ROCHA AM, DEAMAS, AM, DE OLIVEIRA CA. The interrelationship between Helicobacter pylori vacuolating by toxin and gastric carcinoma. Am J Gastroenterol 1998; 93: 1841-7.
3. WELL JFK, VANDERHULTS RW, GERRITS T. Heterogeneity in susceptibility to metronidazole among Helicobacter pylori isolated from patients with gastritis or peptic ulcers disease. J Clin Microbiol 1996; 34: 2158-62.
4. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-9.
5. BAZZOLI F, ZAGARI P, POZZATO O, VAROLI S, FOSSI L, RICCIARDIELLO G ET AL. Evaluation of short term low-dose triple therapy for eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment Pharmacol Ther 1998; 12: 439-45.
6. VCEV A, VCEVA A, STIMAC D, TAKAC B, DMITROVIC B. Omeprazole, azithromicyn and either amoxycillin or metronidazole in eradication of Helicobacter pylori in duodenal ulcer patients. Aliment Pharmacol Ther 1998; 12: 453-6.
7. BIANCHI G, PARENTE F, LAZARONI M. Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth substrate plus antibiotics or sucralphate alone. Gut 1993; 34: 466-9.
8. FENNERTY MB. Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance. Am J Gastroenterol 1998; 93: 2-3.
9. SISSON G, JEONG J-Y, GOODWIN A, BRYDEN L, ROSSLER N, LIM-MORRISON S ET AL. Metronidazole activation is mutagenic and causes DNA fragmentation in Helicobacter pylori and in Escherichia coli containing a cloned H. pylori rdxA+ (nitroreductase) gene. J Bacteriol 2000; 182: 5091-6.
10. ALARCÓN T, DOMINGO N, PRIETO P, LÓPEZ-BREA M. Clarithromycin resistance stability in Helicobacter pylori: influence of the MIC level and type of mutation on the 23S RNA. Gut 1999; 45: A106 (14/05).
11. GOODWIN S. Detection of H pylori infection by biopsy urease, histology, and culture. In: Clayton C and Mobley H eds. Helicobacter pylori protocols. Totowa, New Jersey, Humana Press. 1997. Pp 7-29.
12. SCHNELL G, SHUBERT T. Usefulness of culture, histology, and urease testing in detection of C. pyloridis. Am J Gastroenterol 1989; 84: 132-7.
13. NATIONAL COMMITTEE FOR CLINICAL LABORATORY STANDARDS. Performance standards for antimicrobial disk susceptibility tests, 3th ed. Approved Standard. NCCLS Documents M2-A3. National Committee for Clinical Laboratory Standards, Wayne, Pa. B
14. BOYANOVA L, STANCHEVA I, SPASSOVA Z, KATZAROV N, MITOV I, KOUMANOVA R. Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria. J. Med Microbiol 2000; 49: 415-8.
15. FLORES S, OPAZO H, VALDERRAMA D, AGUILERA R, MARCHESE A, VALDERRAMA S. Terapia triple de corto tiempo con azitromicina, amoxicilina y omeprazol para la erradicación de Helicobacter pylori. Rev Méd Chile 2000; 128: 509-12.
16. ADAMEK RJ, SUERBAUM S, PKAFFENBACH B. Primary and acquired Helicobacter pylori resistance to Clarithromycin, Metronidazole and Amoxicillin. Influence on treatment outcome. Am J Gastroenterol 1993; 93: 386-9.
17. PARASAKTHI M, GOH MB. Metronidazole resistance among Helicobacter pylori strains in Malaysia. FEMS 1992; 87; 808-11.
18. QUEIROZ DMM, BARBOSA DVC, RODRA EM, MENDES AMR, OLIVEIRA PP, MAGALHAES TF ET AL. Evaluation of factors associated to Helicobacter pylori resistance to drugs. Gut 1999; 45: A113 (14/29).
19. VÁSQUEZ Y, VALDÉS R, GUMAN JJ, MC DONALD TU, WESTBLOM D, BERG D ET AL. Metronidazole and clarithromycin resistance in Helicobacter pylori. Determined by measuring MICs of Antimicrobial agents in color indication egg yolk agar in a miniwell format. J Clin Microbiol 1996; 34: 1232-4.
20. DE KOSTER E. Resistance of Helicobacter pylori to antibiotics. Res Clin Forums 1998; 20: 49-52.
21. DE KOSTER E, CAZZOLI A, VANDENBORE C. Helicobacter pylori resistance to macrolides increases, to imidazoles remains. AGA Disease Week, May 10-16 1997: A 1619.
22. GOODWIN CS. Prevention of nitroimidazole resistance in Helicobacter pylori by coadministration of colloidal bismuth subcitrate: Clinical an in vitro studies. J Clin Pathol 1988; 41: 207-10.
23. WILLIAMSON R, PIPKIN GA. Does bismuth prevent antimicrobial resistance of Helicobacter pylori? Bismuth an eradication of H pylori. Basic Mechanisms to clinical cure, 1998. Hunt RH, Tytgat GN, eds. Kluwer Academic Publishers, London. Pp. 416-25.